[go: up one dir, main page]

MX2023007869A - Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. - Google Patents

Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.

Info

Publication number
MX2023007869A
MX2023007869A MX2023007869A MX2023007869A MX2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A
Authority
MX
Mexico
Prior art keywords
compounds
activation protein
protein ligand
fibroblast activation
formula
Prior art date
Application number
MX2023007869A
Other languages
English (en)
Inventor
Frank Osterkamp
Ulrich Reineke
Christiane Smerling
Christian Haase
Matthias Paschke
Dirk Zboralski
Eberhard Schneider
Aileen Höhne
Jan Ungewiss
Anne Bredenbeck
Hacht Jan Lennart Von
Jessica Wahsner-Teschner
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of MX2023007869A publication Critical patent/MX2023007869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) (ver Fórmula) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X) (ver Fórmula).
MX2023007869A 2021-01-07 2022-01-07 Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. MX2023007869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163134704P 2021-01-07 2021-01-07
PCT/EP2022/050280 WO2022148843A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
MX2023007869A true MX2023007869A (es) 2023-09-22

Family

ID=80050672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007869A MX2023007869A (es) 2021-01-07 2022-01-07 Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.

Country Status (11)

Country Link
US (1) US20230212549A1 (es)
EP (1) EP4274835A1 (es)
JP (1) JP2024503637A (es)
KR (1) KR20230129261A (es)
CN (1) CN116940585A (es)
AU (1) AU2022205523A1 (es)
CA (1) CA3206863A1 (es)
CL (5) CL2023001991A1 (es)
IL (1) IL303925A (es)
MX (1) MX2023007869A (es)
WO (1) WO2022148843A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072092A1 (en) * 2016-06-24 2022-03-10 University Of Iowa Research Foundation Compositions and methods of treating melanoma
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN118647415A (zh) 2022-02-09 2024-09-13 诺华股份有限公司 包含225锕标记的络合物和铋多价螯合剂的药物组合物
WO2024198836A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
WO2024198837A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118754936A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118930606A (zh) * 2023-05-11 2024-11-12 成都纽瑞特医疗科技股份有限公司 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用
US20250049970A1 (en) * 2023-06-14 2025-02-13 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
US20250034210A1 (en) * 2023-06-14 2025-01-30 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
AU2024303797A1 (en) * 2023-06-14 2025-12-04 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
US20250186541A1 (en) * 2023-11-27 2025-06-12 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
TW202532108A (zh) 2024-02-01 2025-08-16 瑞士商諾華公司 治療癌症的方法
WO2025179031A1 (en) * 2024-02-21 2025-08-28 Abdera Therapeutics Inc. Antibody linker conjugates
WO2025179168A1 (en) * 2024-02-22 2025-08-28 Mariana Oncology Inc. Synthesis of dll3-binding peptides
CN121045338A (zh) * 2025-11-05 2025-12-02 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CN1163594C (zh) 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
CA2681351A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
JP2012503670A (ja) 2008-09-25 2012-02-09 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 選択的セプラーゼ阻害剤
AU2010301105A1 (en) 2009-10-02 2012-04-19 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
KR101780131B1 (ko) 2010-08-13 2017-09-19 로슈 글리카트 아게 항-fap 항체 및 이의 사용 방법
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
EP3468619A1 (en) 2016-06-10 2019-04-17 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116617420A (zh) 2017-10-23 2023-08-22 约翰霍普金斯大学 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途
EP3763726A1 (en) * 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Also Published As

Publication number Publication date
KR20230129261A (ko) 2023-09-07
CA3206863A1 (en) 2022-07-14
CN116940585A (zh) 2023-10-24
CL2024001596A1 (es) 2024-10-11
EP4274835A1 (en) 2023-11-15
AU2022205523A1 (en) 2023-07-13
CL2024001599A1 (es) 2024-10-11
CL2024001600A1 (es) 2024-10-11
IL303925A (en) 2023-08-01
CL2023001991A1 (es) 2023-12-15
US20230212549A1 (en) 2023-07-06
CL2024001597A1 (es) 2024-10-11
JP2024503637A (ja) 2024-01-26
WO2022148843A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MX2023007869A (es) Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.
CL2022000016A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo
RU2012147267A (ru) Эффективные аналоги компстатина
ATE540054T1 (de) Antimikrobielle theta defensine und verfahren zu deren verwendung
JP2013177403A5 (es)
CO6150201A2 (es) Anticuerpo humanizado contra beta amiloide
RU2008120027A (ru) Анти-addl моноклональное антитело и его применение
PE20181889A1 (es) Preparaciones que contienen anticuerpos
RU2016147080A (ru) Модуляция активности комплемента
CA2651990C (en) Improved antimicrobial peptides
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
Suwal et al. Synthesis of libraries of peptidomimetic compounds containing a 2-oxopiperazine unit in the main chain
JP2019123717A (ja) ベータ−ヘアピンペプチド模倣体
RU2015146739A (ru) Комплексы типа сахаридная цепочка-полипептид
AR128023A1 (es) Ligandos de anhidrasa carbónica ix
ATE435870T1 (de) Aus ll-37 abgeleiteten peptidinhibitoren von toxinen
ES2607490T3 (es) Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen
CO2023005074A2 (es) Péptido inhibidor de la autofagia y sal de ácido orgánico del mismo que aborda problemas de permeabilidad vascular
BR112015018283A2 (pt) Composto peptídico agonista e composição farmacêutica ou veterinária
CL2024001254A1 (es) Ligandos de receptor de péptido inhibidor gástrico
DK1691827T3 (da) Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock
RU2013145467A (ru) Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1
CO2024010813A2 (es) Inhibidor de tsp1
CR20240470A (es) Péptido con actividad antimicrobiana
DE602005020755D1 (de) Peptidträger für die verabreichung von arzneimitteln